Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia
Conditions
Keywords
CDX-1140, Solid Tumors, Liver Cancer, GI Cancer, Kidney Cancer, Celldex, Monoclonal, Antibody, CD40, CD-40, Flt3l, CDX-301, Lung Cancer, Bile duct cancer, TNBC, RCC, Non-Hodgkin Lymphoma, Follicular Lymphoma, Dendritic cell, Keynote A-23, pembrolizumab, Keytruda, Chemotherapy, Gemcitabine, Nab-paclitaxel, CD40L, CD40 Ligand, Pancreas cancer, Metastatic pancreas cancer, Unresectable pancreas cancer, Stage IV pancreas cancer, Squamous cell cancer lung, Non-squamous cell cancer lung, Metastatic lung cancer, Stage IV lung cancer, Squamous cell cancer of head and neck, Stage IV cancer of head and neck, Throat cancer, Oropharyngeal cancer, Laryngeal cancer, Oral cancer, FLT3 Ligand, fms-like tyrosine kinase 3 ligand, KEYTRUDA®
Brief summary
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Detailed description
This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2), pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer. Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-1140. The dose-escalation part of the study will test the safety profile of CDX-1140, alone or in combination with CDX-301, pembrolizumab or chemotherapy and determine which dose(s) of CDX-1140 will be studied in the expansion portions of the study. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
Interventions
DRUGCDX-1140
CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
DRUGCDX-301
CDX-301 will be injected once a day for five days before Cycles 1 and 2.
DRUGpembrolizumab
pembrolizumab will be administered every 3 weeks.
DRUGChemotherapy
Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
Sponsors
Merck Sharp & Dohme LLC
Celldex Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Recurrent, locally advanced or metastatic melanoma (including mucosal and/or ocular), bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast, colorectal, gastric, esophageal, renal cell, hepatic, ovarian fallopian or primary peritoneal carcinoma, head and neck, and cholangiocarcinoma. Additional tumor types (except primary CNS tumors) may be enrolled after discussion with, and approval from, the medical monitor. 2. Must have received all standard of care therapies (approved or unapproved) as deemed appropriate by the treating physician. Patients who refuse standard therapy are excluded from the study. 3. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment 4. Willingness to undergo a pre-treatment and on-treatment biopsy, if required. Additional Inclusion Criteria for Part 1: 1. Advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, or indolent B-cell lymphoma are also eligible. 2. Lymphoma patients must have received ≥ 1 prior systemic therapy Additional Inclusion Criteria for Part 3: 1. Patients must have documented progression while receiving anti-PD-1 or anti-PD-L1 based regimens for FDA approved indications 2. Patients cannot have received more than one anti-PD-1 or anti-PD-L1 based regimen Additional Inclusion Criteria for Part 4: 1\. Patients must have metastatic pancreatic adenocarcinoma, and have not received previous treatment in a metastatic setting Key
Exclusion criteria
1. History of severe hypersensitivity reactions to other monoclonal antibodies. 2. Previous treatment with any anti-CD40 antibody or with FLT3L. 3. Inadequate washout period from prior therapy as defined in the Protocol. 4. Major surgery within 4 weeks prior to study treatment. 5. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment. 6. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. For all other cancers, the patient must be disease-free for at least 3 years to be allowed to enroll. 7. Active, untreated central nervous system metastases. 8. Active autoimmune disease or documented history of autoimmune disease. 9. History of (non-infectious) pneumonitis or has current pneumonitis. 10. Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | From first dose through 30 days after last dose | The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical benefit rate | Every 8-12 weeks, starting with first dose until disease progression, assessed up to approximately 1-3 years | The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months |
| Duration of Response | First occurrence of a documented objective response to disease progression or death (up to approximately 1-3 years) | The interval from which measurement criteria are first met for CR or PR until the first date that progressive disease is objectively documented |
| Progression-free survival | From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 1-3 years) | The time from start of study drug to time of progression or death, whichever occurs first |
| Objective Response Rate | Every 8-12 weeks, starting with first dose until disease progression, assessed up to approximately 1-3 years. | The percentage of patients who achieved a confirmed complete response or partial response by evaluation criteria in solid tumors for immune-based therapeutics (iRECIST; for solid tumor patients) and the lymphoma response to immunomodulatory therapy criteria (LYRIC; for lymphoma patients). |
| Immunogenicity evaluation | Prior to each dose of study treatment and at treatment discontinuation, up to approximately 1-3 years | Serum samples will be obtained for assessment of human anti-CDX-1140 and anti-CDX-301 antibodies |
| Pharmacokinetic evaluation | Prior to each study treatment, multiple timepoints after each study treatment, and at treatment discontinuation up to approximately 1-3 years | CDX-1140 and CDX-301 concentrations will be measured |
| Overall survival | The time from start of study drug to death from any cause (up to approximately 1-3 years) | The time from start of study drug to death |
Countries
United States
Outcome results
None listed